They have reported distinct LC3A expression patterns in breast [33], endometrial [34], pulmonary carcinoma [35], cutaneous SCC [36], urothelial cell carcinoma (UCC) [37] and colorectal cancer [38], using an anti-LC3A antibody from Abgent (AP1805a). The gene discussed is MAP1LC3A; the disease is transitional cell carcinoma.